Using the COmplex PAthway SImulator, Stage Analysis, and Chemical Kinetics to Develop a Novel Solution to Lower Tau Concentrations in Alzheimer’s Disease

Alzheimer’s is a disease which afflicts 5.5 million Americans. In this study, we asked whether a Tau immunotherapy treatment, Hsp70 protein treatment, or dual treatment approach of both the Tau imunotherapy treatment and Hsp70 protein treatment leads to a greater reduction in Tau protein concentration. As a high concentration of Tau protein is directly related to Dementia and Alzheimer’s, the proposed treatment which reduces the Tau protein concentration the most is the best Alzheimer’s/Dementia treatment. We determined through our experimentation that the Tau immunotherapy treatment results in the least Tau protein concentration in early and advanced cases, less than the joint treatment and single Hsp70 protein treatment. However, the joint treatment was more effective at reducing Tau levels when initial Tau levels were consistent with those found in medium stage Alzheimer’s. The dual treatment had similar effects as the immunotherapy treatment, but with less impacts to Tau concentration. The Hsp70 treatment slowed the increase in Tau concentration, delaying the simulated progression of the disease but not stopping the disease. However, the Hsp70 treatment had the lowest standard deviation, demonstrating it is the most consistent treatment. Overall, we were able to display that the effectiveness of the treatment ultimately relies on the stage of Alzheimer’s.